Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma
Condition(s):LeiomyosarcomaLast Updated:March 25, 2024Recruiting
Hide Studies Not Open or Pending
Condition(s):LeiomyosarcomaLast Updated:March 25, 2024Recruiting
Condition(s):Sarcoma; Melanoma; Lung Cancer; Breast Cancer; Esophageal Cancer; Cervical Cancer; Head and Neck CancerLast Updated:March 15, 2023Completed
Condition(s):Advanced AngiosarcomaLast Updated:May 12, 2020Completed
Condition(s):CancerLast Updated:May 30, 2017Completed
Condition(s):Liposarcoma, DedifferentiatedLast Updated:March 26, 2024Recruiting
Condition(s):CancerLast Updated:July 6, 2016Completed
Condition(s):CancerLast Updated:April 26, 2011Completed
Condition(s):Sarcoma; Ovarian Neoplasm; Central Nervous System Neoplasm; Thyroid Neoplasm; Carcinoma, Neuroendocrine; Neoplasms, Germ Cell and Embryonal; NK/T-cell LymphomaLast Updated:February 28, 2024Completed
Condition(s):Solid TumorLast Updated:March 16, 2023Recruiting
Condition(s):Cancer; Leukemia; Sarcoma; Germ Cell Cancer; Lymphoma; Colorectal Cancer; Melanoma; Breast CancerLast Updated:February 23, 2024Not yet recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.